EGFR and non-small cell lung carcinoma: However, regardless bortezomib limited efficacy in unselected NSCLC patients [52], we demonstrated that proteasome inhibition might represent a valid therapeutic strategy to bypass NF-κB-mediated EGFR-TKI resistance in selected patients.